Onconova Therapeutics Stock Price, News & Analysis (NASDAQ:ONTX)

$1.40 0.03 (2.19 %)
(As of 12/13/2017 03:45 PM ET)
Previous Close$1.37
Today's Range$1.32 - $1.45
52-Week Range$1.32 - $3.88
Volume160,600 shs
Average Volume130,990 shs
Market Capitalization$14.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1

About Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics logoOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Debt-to-Equity RatioN/A
Current Ratio0.97%
Quick Ratio0.97%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.55 million
Price / Sales2.72
Cash FlowN/A
Price / CashN/A
Book Value$0.76 per share
Price / Book1.84

Profitability

Trailing EPS($2.77)
Net Income$-19,660,000.00
Net Margins-2,855.94%
Return on Equity-558.97%
Return on Assets-144.30%

Miscellaneous

Employees23
Outstanding Shares10,770,000

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics's stock reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) issued its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.02. The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. View Onconova Therapeutics' Earnings History.

Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?

4 brokerages have issued 1 year target prices for Onconova Therapeutics' shares. Their predictions range from $6.00 to $10.00. On average, they anticipate Onconova Therapeutics' share price to reach $7.33 in the next twelve months. View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:

  • 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (12/12/2017)
  • 2. HC Wainwright analysts commented, "Positives from the quarter: 1) IPXL launched additional strengths of generic Focalin XR extended-release capsules CII, 25 and 35mg, 2) The company announced the approval and AB rating for generic Concerta ER tablets USP CII, 18, 27, 36, and 54mg, 3) Settled contract litigation on Opana ER CII extended- release tablets, 4) Announced business combination with Amneal, still targeting a 1H18 close, will invest in Specialty Pharma and adjacent businesses, will focus on CNS and expand beyond that into other areas as well, 5) Good progress on operational and cost improvement plans, 6) Positive results from Phase 2b Study of IPX203, with meaningful efficacy benefit over Rytary, 7) In late- stage negotiations for the sale of its Taiwan manufacturing facility. If IPXL is successful in selling its Taiwan facility by the end of 1Q18, IPXL could realize the anticipated cost savings by the end of 2018, ~1 year ahead of schedule., 8) IPXL says it is thinking about creating its own captive distribution system because of the leverage buying consortiums have on customers, And, 9) The possible entry of online vendors, such as Amazon, into generics, improves access to generic drugs, but may not improve pricing. Volumes will likely start slow and grow over time." (11/9/2017)
  • 3. Maxim Group analysts commented, "Onconova reported 3Q17 with a net loss of $7M and ended the period with $7.6M in cash. We forecast that Onconova will need to raise capital. The question then is, at what valuation and how much? The next catalyst for the company is the interim analysis of the INSPIRE pivotal phase 3 trial in Myelodysplastic Syndrome, which is expected in 4Q17. The interim analysis is dependent on reaching 88 events (deaths). Several scenarios could play out which we have profiled in prior notes and below. Conclusion: Good data will drive this company and set the stage to raise additional capital." (11/9/2017)

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:

  • Michael M. B Hoffman, Chairman of the Board (Age 66)
  • Ramesh Kumar Ph.D., President, Chief Executive Officer, Director (Age 59)
  • Mark Guerin, Chief Financial Officer (Age 47)
  • Steven M. Fruchtman M.D., Senior Vice President - Research and Development, Chief Medical Officer (Age 64)
  • Manoj Maniar Ph.D., Senior Vice President - Product Development (Age 52)
  • Henry S. Bienen Ph.D., Director (Age 76)
  • Jerome E. Groopman M.D., Director (Age 63)
  • Viren Mehta Ph.D., Director (Age 65)
  • E. Premkumar Reddy Ph.D., Director (Age 71)
  • Jack E. Stover CPA, Director (Age 64)

Who owns Onconova Therapeutics stock?

Onconova Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (3.48%). Company insiders that own Onconova Therapeutics stock include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?

Onconova Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including 683 Capital Management LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy Onconova Therapeutics stock?

Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of Onconova Therapeutics stock can currently be purchased for approximately $1.40.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $14.76 million and generates $5.55 million in revenue each year. The biopharmaceutical company earns $-19,660,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. Onconova Therapeutics employs 23 workers across the globe.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (ONTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Onconova Therapeutics (NASDAQ:ONTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.33$7.33$17.00$17.00
Price Target Upside: 435.28% upside283.94% upside790.05% upside776.29% upside

Onconova Therapeutics (NASDAQ:ONTX) Consensus Price Target History

Price Target History for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ:ONTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017HC WainwrightSet Price TargetBuy$6.00MediumView Rating Details
11/9/2017Maxim GroupSet Price TargetBuy$6.00N/AView Rating Details
7/25/2017Dawson JamesReiterated RatingBuyHighView Rating Details
4/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00LowView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Onconova Therapeutics (NASDAQ:ONTX) Earnings History and Estimates Chart

Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ ONTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.73)($0.71)$0.29 million$0.11 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.72)($0.29)$0.25 million$0.32 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.96)($1.23)$0.21 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.82)($0.29)$1.60 million$1.70 millionViewN/AView Earnings Details
8/15/2016Q2($1.96)$2.25 millionViewN/AView Earnings Details
5/11/2016Q1($0.19)($0.27)$1.34 million$1.47 millionViewN/AView Earnings Details
3/28/2016Q4($0.27)$0.18$9.60 millionViewN/AView Earnings Details
11/11/2015Q3($0.32)($0.26)$0.11 million$1.62 millionViewN/AView Earnings Details
8/13/2015Q2($0.56)($0.41)$0.11 million$0.12 millionViewN/AView Earnings Details
5/14/2015Q1($0.63)($0.57)$0.11 million$0.11 millionViewN/AView Earnings Details
3/26/2015($0.71)($0.62)$0.11 millionViewN/AView Earnings Details
11/13/2014($0.78)($0.69)$0.11 millionViewN/AView Earnings Details
8/13/2014($0.89)($0.77)$0.56 million$0.13 millionViewN/AView Earnings Details
5/12/2014($0.78)($0.87)$1.32 million$0.45 millionViewN/AView Earnings Details
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details
9/6/2013Q213($5.21)$0.22 million$0.59 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Onconova Therapeutics (NASDAQ:ONTX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.72)($0.72)($0.72)
Q3 20171($0.73)($0.73)($0.73)
Q4 20171($0.74)($0.74)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Onconova Therapeutics (NASDAQ ONTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 29.10%
Institutional Ownership Percentage: 25.44%
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Institutional Ownership by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ ONTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/26/2017E Premkumar ReddyDirectorBuy119,048$2.10$250,000.80View SEC Filing  
4/26/2017Mark Patrick GuerinCFOBuy1,429$2.10$3,000.90View SEC Filing  
4/26/2017Ramesh KumarInsiderBuy23,810$2.10$50,001.00View SEC Filing  
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.60View SEC Filing  
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.00View SEC Filing  
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.00View SEC Filing  
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.00View SEC Filing  
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Onconova Therapeutics (NASDAQ ONTX) News Headlines

Source:
DateHeadline
Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 MeetingOnconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting
finance.yahoo.com - December 12 at 10:39 AM
Onconova Therapeutics (ONTX) PT Set at $6.00 by HC WainwrightOnconova Therapeutics (ONTX) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - December 12 at 9:28 AM
Onconova Therapeutics Inc (ONTX) Given Average Rating of "Hold" by AnalystsOnconova Therapeutics Inc (ONTX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 12 at 3:46 AM
Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings?Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings?
finance.yahoo.com - December 9 at 10:12 AM
 Brokerages Expect Onconova Therapeutics Inc (ONTX) Will Post Quarterly Sales of $410,000.00 Brokerages Expect Onconova Therapeutics Inc (ONTX) Will Post Quarterly Sales of $410,000.00
www.americanbankingnews.com - December 8 at 12:58 PM
-$0.72 EPS Expected for Onconova Therapeutics Inc (ONTX) This Quarter-$0.72 EPS Expected for Onconova Therapeutics Inc (ONTX) This Quarter
www.americanbankingnews.com - December 6 at 7:52 AM
 Onconova Therapeutics Inc (ONTX) Given $5.67 Average Target Price by Analysts Onconova Therapeutics Inc (ONTX) Given $5.67 Average Target Price by Analysts
www.americanbankingnews.com - December 4 at 8:54 AM
Does Onconova Therapeutics Inc’s (ONTX) Past Performance Indicate A Weaker Future?Does Onconova Therapeutics Inc’s (ONTX) Past Performance Indicate A Weaker Future?
finance.yahoo.com - November 30 at 4:40 PM
Onconova Therapeutics to Present at the LD Micro Conference in December - GlobeNewswire (press release)Onconova Therapeutics to Present at the LD Micro Conference in December - GlobeNewswire (press release)
globenewswire.com - November 21 at 9:03 AM
Onconova Therapeutics to Present at the LD Micro Conference in DecemberOnconova Therapeutics to Present at the LD Micro Conference in December
finance.yahoo.com - November 21 at 9:03 AM
$410,000.00 in Sales Expected for Onconova Therapeutics, Inc. (ONTX) This Quarter$410,000.00 in Sales Expected for Onconova Therapeutics, Inc. (ONTX) This Quarter
www.americanbankingnews.com - November 20 at 10:32 AM
Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid LeukemiaOnconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia
finance.yahoo.com - November 18 at 10:40 AM
Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual MeetingOnconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting
finance.yahoo.com - November 18 at 10:40 AM
Head to Head Review: Onconova Therapeutics (ONTX) & Alimera Sciences (ALIM)Head to Head Review: Onconova Therapeutics (ONTX) & Alimera Sciences (ALIM)
www.americanbankingnews.com - November 16 at 3:12 AM
Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 14 at 6:30 AM
Onconova Therapeutics (ONTX) CEO Ramesh Kumar on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaOnconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 11 at 8:33 AM
Onconova Therapeutics, Inc. (ONTX) Posts Quarterly  Earnings Results, Beats Expectations By $0.02 EPSOnconova Therapeutics, Inc. (ONTX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - November 10 at 11:10 PM
Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 10 at 2:57 PM
Edited Transcript of ONTX earnings conference call or presentation 9-Nov-17 2:00pm GMTEdited Transcript of ONTX earnings conference call or presentation 9-Nov-17 2:00pm GMT
finance.yahoo.com - November 10 at 2:57 PM
Maxim Group Reiterates Buy Rating for Onconova Therapeutics, Inc. (ONTX)Maxim Group Reiterates Buy Rating for Onconova Therapeutics, Inc. (ONTX)
www.americanbankingnews.com - November 9 at 3:42 PM
Onconova Therapeutics (ONTX) Buy Rating Reiterated at HC WainwrightOnconova Therapeutics' (ONTX) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 9 at 3:42 PM
Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results - NasdaqOnconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - November 9 at 3:20 PM
Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results - GlobeNewswire (press release)Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 10:10 AM
Onconova Therapeutics Inc (ONTX): How Does It Impact Your Portfolio?Onconova Therapeutics Inc (ONTX): How Does It Impact Your Portfolio?
finance.yahoo.com - November 9 at 10:10 AM
Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial ResultsOnconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 10:10 AM
Onconova Therapeutics Inc. to Host Earnings CallOnconova Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 10:10 AM
Onconova Therapeutics, Inc. (ONTX) Scheduled to Post Quarterly Earnings on MondayOnconova Therapeutics, Inc. (ONTX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 6:02 AM
Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 4 at 8:29 AM
Head-To-Head Review: Fortress Biotech (FBIO) versus Onconova Therapeutics (ONTX)Head-To-Head Review: Fortress Biotech (FBIO) versus Onconova Therapeutics (ONTX)
www.americanbankingnews.com - November 2 at 3:18 PM
Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial ResultsOnconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results
feeds.benzinga.com - November 2 at 9:21 AM
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual MeetingOnconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting
finance.yahoo.com - November 2 at 7:19 AM
-$0.66 Earnings Per Share Expected for Onconova Therapeutics Inc (ONTX) This Quarter-$0.66 Earnings Per Share Expected for Onconova Therapeutics Inc (ONTX) This Quarter
www.americanbankingnews.com - October 28 at 9:10 PM
Head-To-Head Analysis: Onconova Therapeutics (ONTX) and Its RivalsHead-To-Head Analysis: Onconova Therapeutics (ONTX) and Its Rivals
www.americanbankingnews.com - October 27 at 9:38 AM
Critical Contrast: Onconova Therapeutics (ONTX) and Baxalta (BXLT)Critical Contrast: Onconova Therapeutics (ONTX) and Baxalta (BXLT)
www.americanbankingnews.com - October 26 at 9:30 AM
Onconova Therapeutics (ONTX) versus The Competition Head to Head ReviewOnconova Therapeutics (ONTX) versus The Competition Head to Head Review
www.americanbankingnews.com - October 23 at 12:54 PM
Syros Pharmaceuticals (SYRS) vs. Onconova Therapeutics (ONTX) Head-To-Head ComparisonSyros Pharmaceuticals (SYRS) vs. Onconova Therapeutics (ONTX) Head-To-Head Comparison
www.americanbankingnews.com - October 20 at 2:28 AM
Head-To-Head Survey: Onconova Therapeutics (ONTX) vs. The CompetitionHead-To-Head Survey: Onconova Therapeutics (ONTX) vs. The Competition
www.americanbankingnews.com - October 17 at 6:24 PM
Onconova Therapeutics to Present Updates at Two Investor Conferences in OctoberOnconova Therapeutics to Present Updates at Two Investor Conferences in October
finance.yahoo.com - October 11 at 6:16 AM
Todays Research Reports on Stocks to Watch: Onconova Therapeutics and Sorrento TherapeuticsToday's Research Reports on Stocks to Watch: Onconova Therapeutics and Sorrento Therapeutics
finance.yahoo.com - October 11 at 6:16 AM
Mid-Afternoon Market Update: Cleantech Solutions Gains After...Mid-Afternoon Market Update: Cleantech Solutions Gains After...
www.nasdaq.com - October 10 at 1:51 AM
Onconova Therapeutics, Inc. (ONTX) Earns Buy Rating from Analysts at HC WainwrightOnconova Therapeutics, Inc. (ONTX) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - October 9 at 8:16 AM
Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric ... - GlobeNewswire (press release)Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric ... - GlobeNewswire (press release)
globenewswire.com - October 5 at 1:56 PM
Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York CityOnconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City
finance.yahoo.com - October 5 at 1:56 PM
Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 2 at 8:42 PM
Critical Contrast: Onconova Therapeutics (ONTX) vs. Its PeersCritical Contrast: Onconova Therapeutics (ONTX) vs. Its Peers
www.americanbankingnews.com - October 1 at 12:08 AM
Cellectar Biosciences (CLRB) Reports Strategic Collaboration with Onconova Therapeutics (ONTX) to Develop New ... - StreetInsider.comCellectar Biosciences (CLRB) Reports Strategic Collaboration with Onconova Therapeutics (ONTX) to Develop New ... - StreetInsider.com
www.streetinsider.com - September 22 at 7:31 AM
Head-To-Head Survey: Onconova Therapeutics (ONTX) versus Sonoma Pharmaceuticals (SNOA)Head-To-Head Survey: Onconova Therapeutics (ONTX) versus Sonoma Pharmaceuticals (SNOA)
www.americanbankingnews.com - September 15 at 10:20 AM
ChemoCentryx (CCXI) & Onconova Therapeutics (ONTX) Financial ContrastChemoCentryx (CCXI) & Onconova Therapeutics (ONTX) Financial Contrast
www.americanbankingnews.com - September 11 at 8:18 PM
Onconova Therapeutics to Participate in Two Investor Conferences in SeptemberOnconova Therapeutics to Participate in Two Investor Conferences in September
finance.yahoo.com - September 6 at 7:14 AM
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results - GlobeNewswire (press release)Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 17 at 6:35 AM

SEC Filings

Onconova Therapeutics (NASDAQ:ONTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Onconova Therapeutics (NASDAQ:ONTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Onconova Therapeutics (NASDAQ ONTX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.